Építés alatt – nem éles oldal
Belépés
Fut, nem toborozFázis nélkül

Evolve China PMCF Study

A legfontosabb adatok

Ki végzi
Stryker Neurovascular
Hol
Kína22 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Fut, nem toboroz
Résztvevők
500 fő, tervezett
Kezdés
2024. ápr. 24.
Várható befejezés
2031. aug.
A vizsgálat típusa
Megfigyeléses
A vizsgált kezelések
  • Surpass Evolve Flow Diverter System
A regiszteradat frissítve
2026. március 30.

Ki vehet részt

Életkor
18 év – 80 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 16 feltétel megnézéseKevesebb

Ki vehet részt

  • Subject age is ≥ 18 and ≤80 years
  • Subject is eligible for Surpass Evolve FDS IFU, and/or physician intends to treat the subject with Surpass Evolve FDS per his/her judgement
  • Subject, or subject's legally authorised representative (LAR) has provided signed informed consent using the Ethics Committee (EC)-approved consent form
  • Subject is willing to comply with scheduled visits and examinations per institutional SOC

Ki nem vehet részt

  • Subject has any non-target intracranial aneurysm treated within 30 days prior to study enrollment
  • Subject has undergone previous treatment where it would interfere with the delivery and/ or placement and/or proper apposition of Surpass Evolve FDS
  • Subject has acute target aneurysm rupture and/or subarachnoid hemorrhage occurred within 30 days prior to enrollment
  • Antiplatelet and/or anticoagulation therapy (e.g. aspirin and clopidogrel) is contraindicated for the subject
  • Female subjects who are pregnant/ nursing, or who are unwilling or unable to take adequate method of contraception prior to the 12-month study follow-up.*; *If the subject becomes pregnant during her participation, the physician will have to evaluate the risk associated to her continuing participation to the rest of the study
  • Enrollment in another trial involving an investigational product and/or drug interfere with study procedure/ results
  • Subject has any condition demonstrated as Warning or Precautions in IFU
  • Subject with an active bacterial infection
  • Subject in whom the angiography demonstrates the anatomy is not appropriate for endovascular treatment, due to conditions such as:; Severe intracranial vessel tortuosity or stenosis; and/or; Intracranial vasospasm not responsive to medical therapy
  • Subject has not received dual anti-platelet agents prior to the procedure
  • Subject has a planned treatment of a non-target aneurysm in the same vascular territory during participation in the study within 12 months post procedure
  • The investigator determined that the health of the patient may be compromised by the patient's enrollment

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

A prospective, multi-center, single-arm, open-label, observational, post-market clinical follow-up. The expected duration of the study is 8 years (including up to 5-years' follow-up). Each subject will be followed up per standard of care (SoC) at each study site.

A vizsgált kezelések

  • Surpass Evolve Flow Diverter System

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Post-Market Clinical Follow-up Study to Evaluate the Long-Term Safety and Effectiveness of Surpass Evolve Flow Diverter System
A regiszteradat frissítve
2026. március 30.